NCT06639607 2026-03-10
PRiME II
Washington University School of Medicine
Phase 1/2 Not yet recruiting
Clinical Trials
52 trialsNCT07210632 2026-02-27
Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)
Vanderbilt-Ingram Cancer Center
Phase EARLY_PHASE1 Not yet recruiting
NCT03340129 2026-02-02
ABC-X
Melanoma Institute Australia
Phase 2 Recruiting
NCT04401774 2026-01-27
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02648997 2026-01-26
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT06466798 2026-01-08
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase 1 Withdrawn
NCT03743662 2026-01-07
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT07031765 2025-12-18
Peds CHAMP1ON
University of Florida
Phase 1 Active not recruiting
NCT02910700 2025-12-17
Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02374242 2025-12-10
ABC
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT03807765 2025-12-04
Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT03233152 2025-11-21
GlitIpNi
Universitair Ziekenhuis Brussel
Phase 1/2 Active not recruiting
NCT02939300 2025-11-14
Ipilimumab and Nivolumab in Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Completed
NCT02696993 2025-11-10
Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03557359 2025-11-03
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Columbia University
Phase 2 Completed
NCT02914405 2025-10-22
MiniVan
University Hospital Southampton NHS Foundation Trust
Phase 1 Active not recruiting
NCT05704933 2025-10-20
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT06712927 2025-09-08
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Stanford University
Phase 2 Recruiting
NCT06519682 2025-08-29
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
The Hospital for Sick Children
Phase NA Recruiting
NCT05341349 2025-07-30
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Phase 1 Active not recruiting
NCT03890952 2025-07-24
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
Rigshospitalet, Denmark
Phase 2 Completed
NCT04003649 2025-07-10
IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM
City of Hope Medical Center
Phase 1 Recruiting
NCT04047706 2025-06-29
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Active not recruiting
NCT06896110 2025-06-26
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
University of Iowa
Phase 1 Enrolling by invitation
NCT06712875 2025-05-29
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Recruiting
NCT06638931 2025-05-28
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT04323046 2025-05-04
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
University of California, San Francisco
Phase 1 Recruiting
NCT05012254 2025-04-09
NIVIPI-Brain
Fundación GECP
Phase 2 Active not recruiting
NCT04239040 2025-03-19
GVAX Plus Checkpoint Blockade in Neuroblastoma
Dana-Farber Cancer Institute
Phase 1 Terminated
NCT03452579 2025-02-28
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
Case Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT04056910 2025-02-27
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
University of Pittsburgh
Phase 2 Completed
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT05302921 2025-01-01
Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Children's National Research Institute
Phase 2 Completed
NCT04195139 2024-12-11
NUTMEG
University of Sydney
Phase 2 Active not recruiting
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT02978404 2024-06-28
Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 2 Completed
NCT02621515 2024-05-06
CA209-322
University Medical Center Groningen
Phase 2 Terminated
NCT03925246 2024-04-02
REVOLUMAB
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03458455 2023-11-01
TREATMENT
Oslo University Hospital
Unknown
NCT02658981 2023-10-06
Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03563729 2023-07-13
MEMBRAINS
Herlev Hospital
Phase 2 Recruiting
NCT03430791 2023-02-02
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Baptist Health South Florida
Phase 2 Terminated
NCT02829931 2023-01-19
Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04434560 2022-07-26
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
Phase 2 Terminated
NCT02716948 2021-11-30
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT03014804 2020-07-24
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT02529072 2020-03-26
AVERT
Duke University
Phase 1 Completed
NCT02648633 2017-05-31
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
University of Virginia
Phase 1 Terminated